{"id":730066,"date":"2023-02-09T07:19:20","date_gmt":"2023-02-09T12:19:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/"},"modified":"2023-02-09T07:19:20","modified_gmt":"2023-02-09T12:19:20","slug":"decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/","title":{"rendered":"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Feb.  09, 2023  (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46<sup>th<\/sup> Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11\u201315, 2023.<\/p>\n<p>The Company will present new data on its lead investigational gene therapy product candidate, DB-OTO, as well as new data across its gene therapy pipeline. Decibel will also present additional data from the interim analysis of the Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy.<\/p>\n<p>\n        <em>Podium Presentations<\/em>\n      <\/p>\n<p>\n        <strong>Podium 1 | Precise Targeting of GJB2 Cells Results in Safe and Efficacious Gene Therapy in a Rodent Model of Hearing Loss Due to GJB2 Deficiency<\/strong><br \/>\n        <br \/>Presenter: Kathryn Ellis, Ph.D.<br \/>Session Title: Gene Therapy <br \/>Date &amp; Time: Saturday, February 11, 2:00 \u2013 4:00 p.m. ET<\/p>\n<p>\n        <strong>Podium 26 | Development of DB-020, a Locally Administered Product for Protection Against Cisplatin-Induced Ototoxicity<\/strong><br \/>\n        <br \/>Presenter: John Lee<br \/>Session Title: Cisplatin Ototoxicity<br \/>Date &amp; Time: Tuesday, February 14, 10:30 a.m. \u2013 12:30 p.m. ET<\/p>\n<p>\n        <em>Poster Presentations<\/em>\n      <\/p>\n<p>\n        <strong>SU83 | Development of a Platform for Parallel Functional Evaluation of Cell Type Specific Synthetic Promoters for Gene Therapy<\/strong>\n      <\/p>\n<p>\n        <strong>SU84 | Dual Vector Gene Therapy Approaches for STRC-Related Hearing Loss<\/strong>\n      <\/p>\n<p>\n        <strong>MO83 | Nonclinical Pharmacology, Biodistribution, and Safety Studies Supporting the Clinical Development of DB-OTO (AAV1-Myo15-hOTOFv5) for Hearing Loss Due to Genetic Otoferlin Protein Deficiency<\/strong>\n      <\/p>\n<p>\n        <strong>TU83 | Development of a Utricle Culture System for Exploring Dual AAV-Mediated Expression Kinetics of Human Otoferlin<\/strong>\n      <\/p>\n<p>\n        <strong>TU232 | Advancing Bioinformatically Informed Targets to Achieve <\/strong><br \/>\n        <strong><br \/>\n          <em>In Vivo<\/em><br \/>\n        <\/strong><br \/>\n        <strong> Vestibular Regeneration<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <br \/>About Decibel Therapeutics<\/strong><br \/>\n        <br \/>Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing\u00a0transformative treatments to restore and improve hearing and balance, one of the largest areas of\u00a0unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics\u00a0and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the\u00a0treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment\u00a0of acquired hearing and balance disorders. Decibel\u2019s pipeline, including its lead gene therapy product\u00a0candidate, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of\u00a0creating a world of connection for people with hearing and balance disorders. For more information\u00a0about Decibel Therapeutics, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YkjYWETDp_LbO1BVPJdaQU3khXOoDCj8NLC6wgadprXJ5P_iXrHf2_U_h-mFZfCHBcPJ_Boh8_pqh0itZYA55g==\" rel=\"nofollow noopener\" target=\"_blank\">www.decibeltx.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GpDtvlqTKztXmzyLOWxXi1Z6v8zueMLqKHUA5uFfVeGza2wzJWW5tGPZ0In1JJZ9u5xjl7U1JZV4rnU4cm-5Ag==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Julie Seidel<br \/>Stern IR, Inc.<br \/>212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u5pmUWKdd-zrl1M882cytTWmCaIBywdfOOPwnaP5O5npLeW-X17fATf6qQUrRrQqXLqg_x_ot6JzR0F6wgUbcdWeI6Ily_TGgZOTKzRdybg=\" rel=\"nofollow noopener\" target=\"_blank\">Julie.seidel@sternir.com<\/a><\/p>\n<p><strong>Media Contact:<\/strong><br \/>Chris Railey<br \/>Ten Bridge Communications<br \/>617-834-0936<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_zZFEnLLish3ldlEjs0QMlyjwBMdqZzzPcFuu8I9jQzeAmK1d88EHC9PlEI2sA7-ODs7MwCecGowWRFXAwLNFpdaTZjsnw3C4G4vHh0xntgRmExHAKQaiDevDUtuLzsH\" rel=\"nofollow noopener\" target=\"_blank\">chris@tenbridgecommunications.com<\/a><\/u><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGUwNzRkMGUtZGM1Zi00OTczLTg4ZWQtMWY5MDg1NTEwY2MwLTEyMTczMDY=\/tiny\/Decibel-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11\u201315, 2023. The Company will present new data on its lead investigational gene therapy product candidate, DB-OTO, as well as new data across its gene therapy pipeline. Decibel will also present additional data from the interim analysis of the Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy. Podium Presentations Podium 1 | Precise Targeting &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-730066","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11\u201315, 2023. The Company will present new data on its lead investigational gene therapy product candidate, DB-OTO, as well as new data across its gene therapy pipeline. Decibel will also present additional data from the interim analysis of the Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy. Podium Presentations Podium 1 | Precise Targeting &hellip; Continue reading &quot;Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T12:19:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting\",\"datePublished\":\"2023-02-09T12:19:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/\"},\"wordCount\":449,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/\",\"name\":\"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=\",\"datePublished\":\"2023-02-09T12:19:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting - Market Newsdesk","og_description":"BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11\u201315, 2023. The Company will present new data on its lead investigational gene therapy product candidate, DB-OTO, as well as new data across its gene therapy pipeline. Decibel will also present additional data from the interim analysis of the Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy. Podium Presentations Podium 1 | Precise Targeting &hellip; Continue reading \"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-09T12:19:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting","datePublished":"2023-02-09T12:19:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/"},"wordCount":449,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/","name":"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=","datePublished":"2023-02-09T12:19:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTY2NiM1Mzk5NjkyIzIyMDU3NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-46th-annual-association-for-research-in-otolaryngology-aro-midwinter-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/730066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=730066"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/730066\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=730066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=730066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=730066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}